EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

Brian S Henick iD, Peter D Koch, Justin F Gainor, Mark M Awad iD, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F Garofano, Cheryl V Wong, Anjali Saqi, Jessica Grindheim und 6 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009301 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Brian S Henick und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study of neoadjuvant atezolizumab+chemotherapy.

Methods

This open-label, multicenter single-arm investigator-initiated phase II study conducted at three US hospitals tested up to four cycles of atezolizumab, carboplatin, and nab-paclitaxel prior to surgery. Major pathological response (MPR, primary endpoint) was previously reported; here, we report 3-year disease-free survival (DFS), OS, and clinical characteristics of patients developing brain metastases (BM) with integrated data from tumor genomics, gene expression, and quantitative immunofluorescent measurement of immune markers.

Results

Of 30 enrolled patients, 29 were taken to the operating room. 26 underwent R0 resection, with 17 experiencing MPR (10 pCR). With a median follow-up of 39.5 months, the median OS was 55.8 months, and the median DFS was 34.5 months. Landmark OS at 36 months was 77%. Among 14 patients with recurrent disease, 6 patients had BM. Patients whose tumors had mutations in STK11 and KEAP1 did not have a significantly higher incidence of BM. Reduced copy number of STK11 and KEAP1 , both residing on chromosome 19p, was observed in ~1/3 of tumors. Reduced CN of STK11 was significantly associated with worse pathological response and incidence of BM.

Conclusions

Consistent with recent phase III studies, 3-year OS data with neoadjuvant atezolizumab+chemotherapy was associated with prolonged PFS and OS. Establishing associations between STK11 and KEAP1 genomic alterations and key clinical outcomes in early-stage NSCLC requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedCarboplatinAdultPaclitaxelAMP-Activated Protein Kinase Kinases

Stichwörter der Autor:innen

BiomarkerImmunotherapyLung CancerNeoadjuvant

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedCarboplatinPaclitaxelSTK11 protein, humanAMP-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA bh2682@cumc.columbia.edu at3488@cumc.co…
  • Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Hematology/Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Biostatistics, Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.

ORCID-Profile: Brian S Henick, Mark M Awad, Benjamin Izar

Förderung

  • NCI NIH HHS
  • Genentech

Zitieren

APA

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009301

Vancouver

Henick BS, Koch PD, Gainor JF, Awad MM, Chiuzan C, Izard S, et al. Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009301

BibTeX
@article{Henick2024,
  author = {Henick, Brian S and Koch, Peter D and Gainor, Justin F and Awad, Mark M and Chiuzan, Codruta and Izard, Stephanie and Georgis, Yohanna and Mallick, Samyukta and Garofano, Robert F and Wong, Cheryl V and Saqi, Anjali and Grindheim, Jessica and Schulze, Katja and Sonett, Joshua R and Rizvi, Naiyer A and Izar, Benjamin and Taylor, Alison M and Shu, Catherine A},
  title = {Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009301}
}
Kostenlos starten →